Ga Syfovre denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Syfovre for Medical Necessity — and How to Appeal

Syfovre (pegcetacoplan) is an FDA-approved intravitreal injection for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A medical-necessity denial from Aetna typically means that the clinical documentation submitted with the prior authorization request did not satisfy one or more criteria in Aetna's Clinical Policy Bulletin — most commonly requirements related to confirmed GA diagnosis, lesion characteristics, the specific eye being treated, or the absence of certain concurrent conditions. These denials are not a finding that the drug is inappropriate; they are a finding that the submitted documentation was insufficient.

## Why This Denial Is Appealable

Medical-necessity denials for FDA-approved drugs are among the most commonly reversed on appeal, because the denial is usually driven by incomplete documentation rather than a genuine absence of clinical need. A well-organized internal appeal that maps every policy criterion to a specific chart finding — submitted with a detailed prescriber letter — resolves the documentation gap that caused the initial denial.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: You are entitled to a full-and-fair internal review and access to the specific criteria Aetna applied. You may request the Clinical Policy Bulletin used in the determination.
• External Review: If the internal appeal is denied, an Independent Review Organization (IRO) reviews the case de novo on clinical merits. The standard window to file for external review is approximately four months from the final internal denial. Expedited review is available when delay would cause serious jeopardy to vision or health.

## Appeal Timeline

1. Request the denial letter identifying each unmet criterion. 2. Gather the documentation below and submit the internal appeal. 3. If denied internally, escalate to external review with the same complete package.

## Documentation to Gather

• Diagnosis confirmation: Retinal imaging — such as fundus autofluorescence (FAF), optical coherence tomography (OCT), or color fundus photography — confirming geographic atrophy secondary to AMD, including lesion size and location relative to the fovea.
• Prior-treatment history: Documentation of any prior ocular treatments, their outcomes, and the clinical rationale for now selecting Syfovre.
• Clinical severity documentation: Chart notes from your retina specialist documenting the rate of GA progression, impact on visual function, and the clinical rationale for initiating treatment at this time.
• Prescriber medical-necessity letter: A detailed letter from your retina specialist addressing each criterion in Aetna's policy by name, citing the specific chart finding that satisfies it, and affirming that the use is consistent with the FDA-approved label and applicable professional society guidelines.

## Criteria-Mapping Strategy

Download the current Aetna Clinical Policy Bulletin for Syfovre or intravitreal anti-complement therapy. Create a table with three columns: the policy criterion, the supporting chart document, and the specific finding. Submit this table as a cover sheet to your appeal. Your retina specialist's letter should follow the same structure. Confirm that the FDA-approved prescribing information supports each element of the use being requested. Reference the applicable professional guideline organization (such as the American Academy of Ophthalmology) generically to demonstrate alignment with standard-of-care practice.